Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 6;61(1):2201390.
doi: 10.1183/13993003.01390-2022. Print 2023 Jan.

Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination

Isabell Wagenhäuser  1   2 , Julia Reusch  1   2 , Alexander Gabel  1 , Anna Höhn  1 , Thiên-Trí Lâm  3 , Giovanni Almanzar  4 , Martina Prelog  4 , Lukas B Krone  5   6 , Anna Frey  2 , Alexandra Schubert-Unkmeir  3 , Lars Dölken  7 , Stefan Frantz  2 , Oliver Kurzai  3   8 , Ulrich Vogel  1   3 , Nils Petri  2   9 , Manuel Krone  10   3   9
Affiliations

Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination

Isabell Wagenhäuser et al. Eur Respir J. .

Abstract

Coadministration of seasonal quadrivalent influenza and COVID-19 booster vaccination is safe and does not increase vaccine-related side-effects, but may limit anti-SARS-CoV-2 antibody formation https://bit.ly/3uKFUie

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: M. Prelog received honoraria for presentations at scientific meetings from Abbvie, Chugai-Roche, GSK, Janssen, Novartis, MSD, Pfizer, Sanofi and SOBI, received honoraria for advisory boards from Abbvie, GSK, Janssen, Novartis, Pfizer and BioNTech, received travel scholarships from Chugai-Roche, GSK, Novartis and Pfizer, received financial support for conduction of investigator-initiated research from Baxter, Chugai-Roche, GSK, Novartis, MSD, Pfizer and SOBI; M. Prelog declares to have no conflict of interest regarding the manuscript. M. Krone receives honoraria from GSK and Pfizer, outside the submitted work. All other authors declare no potential conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Anti-SARS-CoV-2-spike IgG concentrations after third dose of COVID-19 vaccine with or without influenza vaccine coadministration, separated for COVID-19 booster vaccine (BNT162b2mRNA or mRNA-1273), logarithmically scaled. ****: p<0.0001 *: p<0.05. BAU: binding antibody units.
See this image and copyright information in PMC

References

    1. Larrauri A, Prosenc Trilar K. Preparing for an influenza season 2021/22 with a likely co-circulation of influenza virus and SARS-CoV-2. Euro Surveill 2021; 26: 2100975. doi:10.2807/1560-7917.ES.2021.26.41.2100975 - DOI - PMC - PubMed
    1. Giordano G, Blanchini F, Bruno R, et al. . Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy. Nat Med 2020; 26: 855–860. doi:10.1038/s41591-020-0883-7 - DOI - PMC - PubMed
    1. Bielicki JA, Duval X, Gobat N, et al. . Monitoring approaches for health-care workers during the COVID-19 pandemic. Lancet Infect Dis 2020; 20: e261–e267. doi:10.1016/S1473-3099(20)30458-8 - DOI - PMC - PubMed
    1. Chotpitayasunondh T, Fischer TK, Heraud JM, et al. . Influenza and COVID-19: what does co-existence mean? Influenza Other Respir Viruses 2021; 15: 407–412. doi:10.1111/irv.12824 - DOI - PMC - PubMed
    1. Izikson R, Bolduc D, Bourron JS, et al. . Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study. Lancet Respir Med 2022; 10: 392–402. doi:10.1016/S2213-2600(21)00557-9 - DOI - PMC - PubMed

Publication types

MeSH terms